Craft

Oramed Pharmaceuticals

Stock Price

$2.3

2024-10-29

Market Capitalization

$94.2 M

2024-10-29

Revenue

$2 M

FY, 2025

Oramed Pharmaceuticals Summary

Company Summary

Overview
Oramed Pharmaceuticals is a pharmaceutical company currently engaged in the research and development of innovative pharmaceutical solutions, including an oral insulin capsule to be used for the treatment of individuals with diabetes, and the use of orally ingestible capsules or pills for delivery of other polypeptides.
Type
Public
Status
Active
Founded
2006
HQ
New York, NY, US | view all locations
Website
http://www.oramed.com/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • Miriam Kidron

    Miriam Kidron, Chief Scientific Officer & Director

    LocationsView all

    3 locations detected

    • New York, NY HQ

      United States

      1185 6th Ave #228

    • ירושלים, מחוז ירושלים HQ

      Israel

      Hi-Tech Park

    • Jerusalem, Jerusalem District

      Israel

      8, ALROV MAMILLA AVENUE

    Oramed Pharmaceuticals Financials

    Summary Financials

    Revenue (FY, 2025)
    $2.0M
    Gross profit (FY, 2025)
    $13.0K
    Net income (FY, 2025)
    $64.0M
    Cash (FY, 2025)
    $45.9M
    EBIT (FY, 2025)
    ($15.1M)

    Footer menu